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Glycogen and lipids are major storage forms of energy
that are tightly regulated by hormones and metabolic
signals. We demonstrate that feeding mice a high-fat
diet (HFD) increases hepatic glycogen due to increased
expression of the glycogenic scaffolding protein PTG/R5.
PTG promoter activity was increased and glycogen levels
were augmented in mice and cells after activation of the
mechanistic target of rapamycin complex 1 (mTORC1)
and its downstream target SREBP1. Deletion of the PTG
gene in mice prevented HFD-induced hepatic glycogen
accumulation. Of note, PTG deletion also blocked hepatic
steatosis in HFD-fed mice and reduced the expression of
numerous lipogenic genes. Additionally, PTG deletion
reduced fasting glucose and insulin levels in obese mice
while improving insulin sensitivity, a result of reduced
hepatic glucose output. This metabolic crosstalk was
due to decreased mTORC1 and SREBP activity in PTG
knockout mice or knockdown cells, suggesting a positive
feedback loop in which once accumulated, glycogen
stimulates the mTORC1/SREBP1 pathway to shift energy
storage to lipogenesis. Together, these data reveal a pre-
viously unappreciated broad role for glycogen in the
control of energy homeostasis.
Glycogen represents the first choice for energy storage
and use. Its metabolism is tightly regulated by both hor-
mones and nutritional status, which control the activities
of glycogen synthase (GS) and glycogen phosphorylase (GP)
through a variety of pathways (1). GS and GP activities are
coordinated by glycogen-targeting subunits that serve as
molecular scaffolds, bringing together these enzymes with
phosphatases and kinases in a macromolecular complex and
in the process, promoting activation of GS and inactivation
of GP. Six different proteins target protein phosphatase 1
(PP1) to glycogen (2). In liver, PTG and GL are expressed at
approximately equivalent levels (3), and together, they fa-
cilitate the mobilization and storage of hepatic glycogen.
PTG overexpression dramatically increases glycogen content
because of a redistribution of PP1 and GS to glycogen par-
ticles and a corresponding marked increase in GS activity
and glycogen synthesis (4–8).
Despite its profound effects, how PTG controls glyco-
gen metabolism remains uncertain. One potential mode
of regulation may be transcriptional. Both noradrenaline
and adenosine upregulate PTG mRNA levels in astrocytes
and hepatocytes concomitant with increased glycogen
synthesis (9). The FoxA2 forkhead class transcription fac-
tor directly binds to and transactivates the PTG promoter
in vitro (10). Moreover, two SREBP/upstream stimulatory
factor–binding units in the PTG promoter also suggest
potential transcriptional regulation by SREBP.
These indications that PTG may be under transcrip-
tional regulation prompted us to study its expression
during various dietary conditions and assess its impor-
tance in energy homeostasis. We show that a high-fat diet
(HFD) produces an increase in hepatic glycogen through
a process that involves induction of PTG mRNA and
protein levels, which occur downstream of mechanistic
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target of rapamycin complex 1 (mTORC1) activation and
SREBP1 induction. Of note, PTG knockout (KO) mice fed
an HFD exhibited not only decreased glycogen levels in
liver but also improved insulin sensitivity as well as
decreased hepatic steatosis, both of which can be attributed
to reduced activation of mTORC1. Taken together, these
data indicate that upon its accumulation in the liver,
glycogen elicits a positive feedback loop involving mTORC1,
resulting in increased expression of lipogenic genes and,
thus, a coordinated synthesis of glycogen and lipids.
RESEARCH DESIGN AND METHODS
Animals
Generation of PTG KO mice has been described previously
(11). These mice had been maintained on a mixed genetic
background, but for these studies, they were crossed 10
times with C57BL/6J mice (The Jackson Laboratory).
Wild-type (WT) littermates were used as controls. At 8–
10 weeks, male mice were either fed an HFD containing
45% fat (D12451; Research Diets Inc.) or continued on
a normal diet (ND) containing 4.5% fat (5L0D; LabDiet)
for the same duration. All mice were maintained in tem-
perature- and humidity-controlled conditions with a 12-h
light/dark cycle and free access to food and water. All
protocols were approved by the University of Michigan
Animal Care and Use Committee.
Antibodies
The following antibodies were used: GS, pGS (S641),
S6K1, pS6K1 (T389), S6, and pS6 (S235/236) (all from
Cell Signaling) and SREBP1 (a gift from J. Horton). PTG
was detected after amylose pull-down (AMPD) assay using
a rabbit polyclonal antibody raised against the murine
PTG sequence as described previously (11). A mouse mono-
clonal antibody raised against RalA (BD Biosciences) and
rabbit polyclonal antibody raised against CREB (Cell Signal-
ing) were used as a loading control for whole-cell lysate
and nuclear extracts, respectively. For detection, a Western
Lightning Plus-ECL Enhanced Chemiluminescence Substrate
kit (PerkinElmer Life Sciences) was used. Individual protein
bands were quantified by NIH ImageJ software.
Glycogen Measurement and Assay of Glucose
Conversion Into Glycogen
Glycogen was measured as previously published (12). The
assay of glucose conversion into glycogen was performed
as previously described (13).
Triglyceride Measurement
Frozen tissues were homogenized in buffer containing 50
mmol/L Tris, 5 mmol/L EDTA, and 30 mmol/L mannitol.
Crude lysate was mixed with potassium hydroxide and
extracted with chloroform:methanol (2:1). After vigorous
vortexing and short incubation, samples were centrifuged
at 13,000 rpm for 10 min. The bottom layer was dried and
resuspended in butanol mixture (3 mL butanol, 1.66 mL
Triton X-114, and 0.33 mL methanol) before assaying the
triglyceride content with a Serum Triglyceride Determi-
nation Kit (Sigma-Aldrich).
Quantitative Real-Time PCR
Total RNA was isolated (Ambion RNA isolation kit; Life
Technologies) and subjected to quantitative real-time PCR
as described previously (14). Primers are listed in Supple-
mentary Table 1.
Western Blotting and AMPD Assay
Whole-cell lysates and nuclear extracts were prepared as
described previously (11,15). AMPD assays were used to
analyze PTG and glycogen-bound GS protein levels.
Briefly, 1 mg total proteins from crude lysates was incu-
bated with amylose resin (New England Biolabs) for 2 h at
4°C before centrifuged down at 3,000 rpm for 2 min.
Proteins bound to the resin were washed and released
by boiling in the presence of SDS sample buffer and sub-
jected to Western blotting.
Luciferase Constructs and Luciferase Reporter Assay
PTG promoter fragments were generated as described pre-
viously (10). The 2493 to +36 fragment was used as a tem-
plate to produce mutations in the putative SREBP binding
sites. The following primer sequences were used in site-
directed mutagenesis: M1, 59-GATTGGTCGGAGGGACCGT
GGCTTTGATAAGCTGCC-39 and 59-GGCAGCTTATCAAAGC
CACGGTCCCTCCGACCAATC-39; M2, 59 GATTGGTCGGAGG
GACCGGTTGTCGTGATCTGGCTTTGATAAG-39and 59- CT
TATCAAAGCCAGATCACGACAACCGGTCCCTCCGACCAAT
C-39; and M3, 59- GTCGGAGGGACCGGTTGTCGACATCTG
GCTTTGATAAGCTGC-39 and 59-GCAGCTTATCAAAGCCA
GATGTCGACAACCGGTCCCTCCGAC-39. Human embryonic
kidney (HEK) 293A and TSC2 murine embryonic fibroblast
(MEF) cells were cultured in DMEM containing 10% FBS.
TSC2-null MEFs were obtained from D. Kwiatkowski
(Brigham and Women’s Hospital) (16). Luciferase reporter
assay was conducted as described previously (10).
Chromatin Immunoprecipitation Assay
TSC2 MEF cells were treated with 1% formaldehyde for 10
min and processed with a chromatin immunoprecipitation
(ChIP) assay kit as described previously (10). An aliquot of
DNA was used for quantitative real-time PCR using the fol-
lowing primers corresponding to the mouse PTG genomic
sequences: P1, 59-CTGGAGTTCCAGGCTGTGTA-39 and 59-
GAGAACGGCTCAGAGGGTAG-39; P2, 59-GGGAAACACACA
CACACACA-39 and 59-GAGAAGTTGGCTGGCTCTTC-39; P3,
59-TCACGTGATCTGGCTTTGAT-39 and 59-CTGAGCAACTTC
GCACTCAG-39; and P4, 59-TTTGATTGGTCGGAGGGA-39
and 59-AACCGGGAGGCAGCTTAT-39.
Blood Glucose and Insulin Measurements
Blood glucose was measured by a OneTouch Ultra glucometer
(LifeScan). Plasma insulin concentrations were measured
by Ultra Sensitive Mouse Insulin ELISA Kit (Crystal
Chem, Inc.).
Glucose, Insulin, and Pyruvate Tolerance Tests
For glucose tolerance tests (GTTs), mice were fasted for 6 h
before an oral injection of glucose (1.5 g/kg body weight).
For insulin tolerance tests (ITTs), mice were fasted for 3 h
before an injection of Humulin R (Eli Lilly) (0.75 units/kg
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body weight i.p. for ND or 1.5 units/kg body weight i.p. for
HFD). For pyruvate tolerance tests (PTTs), mice were fasted
overnight before an injection of sodium pyruvate (1.5 g/kg
body weight i.p.). Blood glucose concentrations were mea-
sured before and after the injection at the indicated time
points using the OneTouch Ultra glucometer.
Short Hairpin RNA Knockdown Experiments
Mouse pGIPZ lentiviral–short hairpin RNA (shRNA)
clones targeting SREBP1 and PTG were provided by the
University of Michigan Biomedical Research Core Facilities.
Lentiviral production was done as described previously (17).
RNA Sequencing and Data Analysis
Total RNA was isolated from livers of biological triplicates
using TRIzol (Invitrogen) and the RNeasy Mini Kit
(Qiagen). Libraries were prepared from 100–500 ng total
RNA (TrueSeq Sample Preparation Kit v2; Illumina) and
sequenced on the Illumina HiSeq 2000 using bar-coded
multiplexing and a 100-bp read length. Data analysis was
accomplished as previously described (16) using UCSC
mm9 as a reference sequence. Heat maps were visualized
using Java TreeView 1.1.6r2 (http://jtreeview.sourceforge
.net). RNA sequencing (RNA-seq) data are available from
the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo)
as accession no. GSE45319.
RESULTS
HFD Increases Hepatic Glycogen in Fasted Mice
To understand better the role of glycogen metabolism in
the overall control of energy disposition, C57BL/6J mice
were fed an HFD for 12 weeks and became obese, glucose
intolerant, and insulin resistant (Supplementary Fig. 1).
Mice were subjected to 16 h of fasting followed by 6 h of
refeeding before kill. Hepatic glycogen levels were almost
completely depleted by fasting and replenished after
refeeding (Fig. 1A). Of note, although levels were similar
in the refed state, HFD produced a threefold increase in
hepatic glycogen levels in fasted mice (Fig. 1A). Hepatic
PTG (Ppp1r3c) mRNA levels were increased approximately
twofold by HFD in both the fasted and the refed states,
concomitant with similar induction in SREBP1 (Srebf1)
mRNA levels (Fig. 1B). Phosphorylation of the mTORC1
downstream target S6K and its substrate S6 was dramat-
ically increased by HFD in fasted mice (Fig. 1C). Fasting
reduced SREBP1 processing; however, we still detected an
increase in the active, mature form of SREBP1 protein
after HFD (Fig. 1C), which is consistent with previous
reports (17,18). PTG protein levels corresponded well
with the HFD-dependent increase in mTORC1 activity
and SREBP1 induction (Fig. 1C), suggesting that the
mTORC1/SREBP1 pathway contributes to the elevated
glycogenesis observed in obesity in the fasted state.
GP activity did not change, ruling out the possibility
that increased glycogen content in obesity results from
reduced GP activity (Fig. 1D). Although total GS protein
levels decreased during refeeding, the mRNA levels of the
predominant GS isoform GYS2 in liver were not changed,
suggesting a posttranscriptional modification of GS in re-
sponse to refeeding (Fig. 1B). Because the GS antibody
might not efficiently recognize the dephosphorylated form
of the enzyme, we measured GS activity (2/+G6P ratio) in
liver lysate and observed increased GS activity in response
to refeeding in the livers of ND-fed but not HFD-fed mice
(Fig. 1E).
The PTG Promoter Is Regulated by SREBP1 and
mTORC1
The coordinated increases in hepatic SREBP1 and PTG
protein and transcript levels in response to nutritional
status and the correlation of these findings with increased
glycogen levels suggested an SREBP-dependent mecha-
nism for the regulation of PTG transcription. Therefore,
we generated mutations of SREBP binding sites on the PTG
promoter (10) and assessed their activities by luciferase-
based promoter assays. Expression of active SREBP-1c led
to an approximately twofold increase in the activity of
the WT PTG promoter, an effect significantly blunted in
the mutants (Fig. 2A), suggesting that SREBP1 modulates
PTG promoter activity through sterol regulatory elements
(SREs) proximal to the transcriptional start site.
To determine whether mTORC1 can regulate PTG
transcript levels, we examined TSC22/2 MEFs that have
high mTORC1 activity (19). PTG promoter activity was
elevated in TSC22/2 cells and was reduced by rapamycin
treatment (Fig. 2B). However, this activation was not seen
in the PTG promoter mutant M1, in which the only avail-
able SRE was deleted. ChIP assay confirmed direct inter-
action of SREBP1 with the PTG promoter, and this
interaction was enhanced at the SREBP1 binding site by
constitutive activation of mTORC1 (Fig. 2C). Similarly,
overexpression of the constitutively active form of Rheb
(20) activated the PTG promoter in a rapamycin-sensitive
manner, and this effect was abolished by deletion of the
proximal SRE in the PTG promoter (Fig. 2D).
Transcriptional Regulation of PTG Expression by
SREBP1 Is Required for the Increased Glycogen
Produced by mTORC1 Activation
TSC22/2 MEFs have increased protein levels of PTG and
SREBP1, higher steady state levels of glycogen, and
a greater rate of glucose conversion into glycogen than
WT MEFs (Fig. 3A, C, and D [control]), suggesting that
mTORC1 activation is sufficient for increased glycogen con-
tent in vitro. Because PTG binds to and localizes PP1 and its
substrate GS to glycogen (4), we performed AMPD assays
to measure PTG and GS bound to a glycogen-like matrix.
Glycogen-bound GS levels increased with PTG (Fig. 3A, con-
trol), explaining the elevated glycogen content in TSC22/2
cells. These data reinforce the notion that PTG plays
a dual scaffolding/dephosphorylation role by recruiting GS
to the glycogen pellet and promoting its dephosphorylation.
To test whether the stimulation of glycogen synthesis
by mTORC1 depends on SREBP1, we performed lentiviral-
mediated shRNA knockdown of SREBP1. The levels
of PTG protein and mRNA were reduced by SREBP1
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knockdown, as was the recruitment of GS to the amylose
precipitate (Fig. 3A and B). Glycogen levels (Fig. 3C) and
the conversion of glucose into glycogen (Fig. 3D) were
similarly reduced. Collectively, these data suggest a role
for mTORC1 in the regulation of PTG gene expression
through SREBP binding to an SRE in the PTG promoter.
PTG Levels Control Glycogen Synthesis and
Contribute to Feedback Regulation of mTORC1 and
SREBP1
Lentiviral-mediated shRNA knockdown of PTG produced
a 60–70% reduction in both protein and transcript levels
of PTG in TSC22/2 cells (Fig. 4A and B). PTG knockdown
Figure 1—HFD increases hepatic glycogen in fasted mice. A: Glycogen content in the liver of C57BL/6J mice fed HFD for 12 weeks and
killed after 16 h of fasting followed by 6 h of refeeding (n = 8 each group). B: Quantitative real-time PCR showing relative mRNA level of
PTG, SREBP1, and GYS2 from the liver of mice in A. C: Representative Western blots from the liver of mice in A. See RESEARCH DESIGN AND
METHODS for details. N.E., nuclear extracts; WCL, whole-cell lysate. D and E: Hepatic GP and GS activity, respectively, from the mice in
A (n = 6–8 mice/group). Data are mean 6 SE. *P < 0.05 by Student t test.
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did not affect other glycogen-targeting subunits, such as
GL, GM, and the catalytic subunit PP1 (Supplementary
Fig. 2A and B and Fig. 4A). Of note, PTG knockdown
also reduced SREBP1 protein and mRNA levels, suggest-
ing a positive feedback mechanism in which PTG regulates
SREBP1.
PTG knockdown produced a 60–70% reduction in both
steady state glycogen content and rate of glycogen syn-
thesis in TSC2/2 but not TSC+/+ cells (Fig. 4C and D),
consistent with the knockdown efficiency of PTG in these
cells. The reduced glycogen synthesis was not due to re-
duced glucose transport because glucose uptake was not
affected by PTG knockdown (Fig. 4E).
We next examined regulation of mTORC1 activity and
glycogen levels by PTG in HEK293A cells in which we
stably overexpressed Flag-GFP–tagged PTG. Glycogen lev-
els in these cells were 50-fold higher than in control cells
(Fig. 4F) because of the constitutive activation of PTG
proteins (Fig. 4G). Moreover, phosphorylation of S6K
was increased twofold in cells overexpressing PTG (Fig.
4G), suggesting that the scaffolding protein also regulates
mTORC1 signaling through a positive feedback mecha-
nism. Taken together, these results provide evidence
that regulation of PTG expression is directly responsible
for the increased glycogen levels in the context of acti-
vated mTORC1.
In HEK293A cells and the liver cell line Hepa1c, we also
observed similar regulation of glycogen synthesis through
PTG. Transient overexpression of WT PTG in these
cells resulted in a two- to threefold increase in glycogen
Figure 2—The PTG promoter is regulated by SREBP1 and mTORC1. A: HEK293 cells were cotransfected with a nuclear active form of
SREBP-1c (aa 1–471) and the indicated reporter constructs of the PTG promoter. Cells were harvested 24 h after transfection and assayed
for luciferase activity. Results were normalized (Renilla luciferase) and expressed as fold increase over the basal value of each construct. B:
TSC2 MEF cells were transfected with the indicated luciferase reporter constructs of the PTG promoter and treated with rapamycin
(100 nmol/L) or DMSO before harvest. C: A schematic representation of the PTG promoter region (top) and ChIP experiment showing
increased SREBP1 activity in TSC22/2 cells (bottom). Cross-linked chromatin was immunoprecipitated with SREBP1 antibody and ex-
tensively washed before elution and precipitation of DNA. Quantitative PCR was performed with the indicated primer pairs. Primer
sequences are listed in RESEARCH DESIGN AND METHODS. D: Effect of Rheb and rapamycin on the PTG promoter activity. HEK293 cells were
cotransfected with Rheb or vector and the indicated luciferase reporter construct of the PTG promoter harboring the deletion of the putative
SREBP1 binding site. Cells were subsequently treated with DMSO or rapamycin (100 nmol/L) for 24 h before harvest and assayed for
luciferase activity. Results were normalized (Renilla luciferase) and expressed as fold increase over the basal value of each construct. Data
are mean 6 SE (n = 3). *P < 0.05 by Student t test. Luc, luciferase; Rapa, rapamycin; TSS, transcription start site.
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content. More importantly, these effects were blocked by
overexpression of PTG mutants that are incompetent to bind
to GS or GP, suggesting that PTG is crucial in the recruitment
of GS and GP to glycogen particles (Supplementary Fig. 2C).
Homozygous Deletion of PTG Reduces Glycogen and
Lipid Levels In Vivo
Our previous studies in PTG heterozygous KO mice
suggested that PTG acts as a PP1 scaffolding protein and
plays a vital role in glycogen metabolism (11). These mice
had been maintained on a mixed background in which
homozygous deletion of the PTG gene was lethal in
the embryonic stage. Subsequent backcrosses of these
mice into a C57BL/6J background produced viable homo-
zygous PTG KO mice (Supplementary Fig. 3A). The geno-
typing of .200 female and male homozygous PTG KO
pups derived from heterozygous breeding pairs coming
from the first backcross accounted for only ;10% of the
total births, a number significantly lower than the expected
Mendelian inheritance ratio of 25% (Supplementary
Fig. 3B). However, sequential backcross of the heterozy-
gous PTG KO mice with C57BL/6J mice produced both
female and male homozygous PTG KO mice born at the
expected frequency (Supplementary Fig. 3B). Although
the mechanism underlying the effect of genetic back-
ground on survival of PTG KO mice remains unknown,
all the experiments described in the current study were
performed on male PTG KO mice derived from heterozy-
gous breeding pairs backcrossed 10 times with C57BL/6J
mice, and littermates without PTG gene deletion (WT)
were used as controls.
To study the role of PTG in glucose homeostasis in
vivo, we fed PTG KO mice an HFD. No obvious differences
in weight gain or food intake were observed between WT
and KO mice fed either ND or HFD, demonstrating that
the PTG KO mouse exhibits a normal growth rate and
eating behavior (Supplementary Fig. 3C and D).
Both hepatic glycogen and triglyceride levels were
greatly reduced in PTG KO mice fed an HFD for 12
weeks (Supplementary Fig. 3E and F). Consistent with the
Figure 3—Transcriptional regulation of PTG expression by SREBP1 is required for the increased glycogen produced by mTORC1 activa-
tion. A: Western blots showing SREBP1 knockdown in TSC2 MEFs. See RESEARCH DESIGN AND METHODS for details. N.E., nuclear extracts;
WCL, whole-cell lysate. Cells were transfected with lentiviral-mediated control shRNA or shRNAs targeting SREBP1 and selected for cells
stably expressing shRNAs. Stable cells were lysed and subjected to Western blotting against indicated antibodies. B: Quantitative real-time
PCR showing relative mRNA level of SREBP1 and PTG from cells in A. C: Glycogen content of cells in A. D: [14C]glucose conversion into
glycogen of cells in A. Data are mean 6 SE (n = 3). *P < 0.05 by Student t test.
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increased hepatic glycogen levels observed in HFD WT
mice, a twofold increase in PTG and SREBP1 mRNA was
detected (Supplementary Fig. 3G). The mRNA levels of the
glycogen-targeting subunit GL were also increased by
about twofold under HFD conditions (Supplementary
Fig. 3G). However, GTTs and ITTs were indistinguishable
between PTG WT and KO mice fed either ND or HFD
(Supplementary Fig. 3H and I). Of note, neither GS nor
GP activity was changed in the liver lysates from KO mice
(Supplementary Fig. 4), reinforcing the hypothesis that
PTG is a crucial scaffold to recruit GS or GP to the glyco-
gen particles. In this regard, it is possible that the
Figure 4—PTG levels control glycogen synthesis and contribute to feedback regulation of mTORC1 and SREBP1. A: Western blots
showing PTG knockdown in TSC2 MEFs. Cells were transfected with lentiviral-mediated control shRNA or shRNAs targeting PTG and
selected for cells stably expressing shRNAs. Stable cells were lysed and subjected to Western blotting against indicated antibodies. B:
Quantitative real-time PCR showing relative mRNA level of PTG and SREBP1 from cells in A. C: Glycogen content of cells in A. D:
[14C]glucose conversion into glycogen of cells in A. E: 2-DG uptake of cells in A. F: Glycogen levels of HEK293A cells stably overexpressing
Flag-tagged PTG. G: Representative Western blots showing activation of mTORC1 activity by overexpressing PTG. Numbers above blots
indicate relative band intensity as quantified by NIH ImageJ software. Data are mean 6 SE (n = 3 experiments). *P < 0.05 by Student t test.
2-DG, 2-deoxy-D-glucose; IB, immunoblotting; IP, immunoprecipitation; N.E., nuclear extracts; n.s., not significant by Student t test; WCL,
whole-cell lysate.
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phosphorylation status or activity of nonglycogen-targeted
GS or GP (i.e., GS or GP in whole-cell lysate) is largely
irrelevant to glycogen accumulation.
We next explored glycogen synthesis more broadly by
directly examining glucose conversion into glycogen in
vitro in isolated primary hepatocytes (Fig. 5A–C) or in
vivo during a hyperinsulinemic-euglycemic clamp study
(Fig. 5D and E). In primary hepatocytes isolated from
mice fed an ND, we observed a 60% reduction in [14C]
glucose incorporation into glycogen in PTG KO mice but
no obvious difference in lipid or CO2 incorporation, which
is consistent with the mild reduction in triglycerides ob-
served in PTG KO mice fed an ND. Both [3H]glucose
incorporation into glycogen and lipids were 40–50%
reduced in PTG KO mice fed an HFD for 8–10 weeks, as
measured in a hyperinsulinemic-euglycemic clamp study, sug-
gesting that both glycogen and lipid synthesis in HFD-fed
mice are reduced when PTG is depleted.
PTG Ablation Reduces Hepatic Steatosis After
Long-term HFD
Because of the profound effects of PTG deletion on lipid
accumulation in liver, we also studied mice fed an HFD for
24 weeks. Similar to what was observed with shorter-term
HFD feeding, the 24-week HFD-induced elevation in
glycogen was prevented in PTG KO mice (Fig. 6A). Tri-
glyceride content was 40% decreased in livers from PTG
KO mice fed an HFD compared with WT littermates, cor-
responding to decreased glycogen levels (Fig. 6B). Moreover,
HFD-induced liver steatosis was significantly attenuated
by PTG ablation, consistent with the marked reduction in
triglycerides (Fig. 6C).
To further investigate alleviation of the hepatosteato-
tic phenotype, we measured the expression of key
metabolic and inflammatory genes in the livers. PTG KO
mice fed an HFD had lower expression of Srebf1 and its
downstream target gene fatty acid synthase (Fasn) (Fig.
6D). Gluconeogenic gene expression was modestly higher
in HFD-fed mice and was not different with PTG ablation
(Fig. 6E). However, glycolytic genes, such as pyruvate ki-
nase isozymes R/L (Pklr) and glucokinase (Gck), which
were more highly expressed in mice fed an HFD relative
to those fed an ND, were expressed at lower levels in PTG
KO mice (Fig. 6E). In addition, HFD-induced expression of
several inflammatory genes and markers of macrophage
infiltration, including F4/80 (Emr1), CD11C (Itgax),
Rantes (Ccl5), and MCP-1 (Ccl2), were reduced in livers
from PTG KO mice (Fig. 6F).
Figure 5—PTG ablation results in decreased glucose incorporation into glycogen and lipids. [14C]glucose incorporation into glycogen (A),
lipids (B), and CO2 (C) in primary hepatocytes isolated from 6- to 8-week-old PTG WT or KO mice fed ND. Data are mean 6 SE (n = 3
triplicate experiments). *Significant P < 0.05 by Student t test. [3H]glucose incorporation into glycogen (D) and lipids (E) during a hyper-
insulinemic-euglycemic clamp study using PTG WT or KO mice fed HFD for 8–10 weeks. Data are mean6 SE (n = 10–12 mice/group). *P<
0.05 by Student t test.
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PTG Ablation Improves Glucose Tolerance and Insulin
Sensitivity After Long-term HFD
These changes in glycogen and lipid metabolism prompted
us to investigate the role of PTG in the overall control of
carbohydrate metabolism. After 24 weeks of HFD, both
hyperglycemia and hyperinsulinemia were attenuated in
PTG KO mice (Fig. 7A). We also performed oral GTTs,
intraperitoneal ITTs, and PPTs. PTG ablation did not af-
fect insulin sensitivity or glucose tolerance in ND-fed mice.
However, PTG KO mice displayed much-improved glucose
tolerance (Fig. 7B) as well as improved sensitivity to intraper-
itoneal injection of insulin (Fig. 7C) and pyruvate (Fig. 7D).
AMPD assays from liver lysates revealed that levels of
glycogen-bound GS protein were increased by HFD
consistent with the HFD-induced elevation in PTG pro-
tein levels (Fig. 7E). Moreover, the increase in glycogen-
bound GS protein was suppressed in PTG KO mice, likely
as a result of the lack of recruitment of GS to glycogen in
the absence of PTG. These data demonstrate that the re-
cruitment of GS to glycogen is elevated in HFD-fed mice
due at least in part to increased PTG protein, causing
increased hepatic glycogen content. Of note, both
mTORC1 activity and SREBP1 levels were greatly attenu-
ated in PTG KO mice, confirming in vivo the feedback
Figure 6—PTG ablation reduces hepatic steatosis in vivo after long-term HFD. A and B: Glycogen content and triglyceride levels, re-
spectively, in the liver of WT and PTG KO mice fed HFD for 24 weeks and fasted overnight (n = 8–10 mice/group). C: Representative
hematoxylin-eosin staining of liver sections of mice in A (scale bars = 200 mm). D: Quantitative real-time PCR showing relative mRNA level
of SREBP1 and fatty acid synthase from mice in A. E and F: Quantitative real-time PCR showing relative mRNA level of glucose metabolism
genes and inflammatory genes and macrophage markers, respectively, from mice in A. TG, triglyceride. *P < 0.05 HFD-KO versus HFD-
WT; #P < 0.05 HFD-WT versus ND-WT.
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regulation of the mTORC1/SREBP1 pathway by PTG and
glycogen.
Taken together, these results suggest that in short-
term HFD-fed PTG KO mice, the reduction in hepatic
glycogen likely contributes to lower glucose output
while mildly reducing serum glucose and insulin levels.
Over time, this modulation of metabolic activity also
leads to dramatically improved insulin sensitivity in the
KO mice, perhaps through reductions in mTORC1
activity known to negatively regulate insulin receptor
signaling (21,22).
A PTG–SREBP1/mTORC1 Feedback Mechanism
Regulates Lipogenesis
Although ablation of PTG did not have a major impact on
systemic glucose tolerance and insulin sensitivity after
short-term HFD, there were dramatic effects on hepatic
lipid metabolism (Fig. 5F), which might reflect a crosstalk
between pools of glycogen and upstream nutrient-sensing
pathways. In an effort to determine the mechanism, we
conducted quantitative real-time PCR for Srebf1 and its
target genes Fasn, Ldlr, and Hmgcr. We observed a trend
toward decreases in the mRNA levels of these genes in the
Figure 7—PTG ablation improves glucose tolerance and insulin sensitivity in vivo after long-term HFD. A: Fasting blood glucose and
insulin levels of WT and PTG KO mice fed HFD for 24 weeks and fasted overnight. B–D: Oral GTTs, ITTs, and PTTs, respectively,
of WT and PTG KO mice fed HFD for 24 weeks. E: Representative Western blot (left) and quantification (right) from the liver
of mice in A. Data are mean 6 SE (n = 8–10). *P < 0.05 by Student t test. N.E., nuclear extracts; OGTT, oral GTT; WCL, whole-cell
lysate.
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PTG KO mice fed HFD, although these changes were not
statistically significant (Fig. 8A).
To thoroughly examine the entire transcriptional land-
scape of PTG WT and KO livers, we performed unbiased
RNA-seq and gene-set enrichment analysis. We found that
sterol, steroid, cholesterol, and lipid biosynthetic/meta-
bolic processes were differentially regulated by PTG
ablation in HFD mice (Fig. 8B). More specifically, the
transcript levels of Srebf1 and its hepatic target genes,
such as Fasn, Ldlr,Mvk, Hmgcr, were significantly reduced
in the PTG KO mice (Fig. 8C and Supplementary Table 2),
consistent with quantitative real-time PCR data. Collec-
tively, these data reveal a novel crosstalk mechanism in
which the mTORC1/SREBP pathway can sense elevated
levels of glycogen and then initiate the transcriptional
changes that increase lipid synthesis.
Figure 8—A PTG–SREBP1/mTORC1 feedback mechanism regulates lipogenesis. A: Quantitative real-time PCR showing relative mRNA
level of SREBP1 and its target genes from the livers of mice fed HFD for 12 weeks and fasted overnight (n = 8–10 mice/group). B: Gene
ontology term enrichment analysis of RNA-seq data from the livers of mice in A. C: Unbiased hierarchical clustering analysis of RNA-seq
data from the livers of mice in A, showing downregulation of SREBP1 hepatic target genes in PTG KOmice fed HFD. Genes shown on the heat
map are listed in Supplementary Table 2. D: A schematic model showing the feedback regulation of PTG and glycogen on mTORC1/SREBP1
and lipogenesis. GO, gene ontology; TG, triglyceride.
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DISCUSSION
Despite its well-established role as the first choice for
energy storage and mobilization, the coordination of
glycogen metabolism with that of lipid synthesis and
breakdown remains poorly understood, particularly in the
liver. The present data reveal that upon reaching thresh-
old levels during nutrient excess, glycogen may trigger
increased expression of lipogenic genes, thus shifting
energy storage from glycogen to lipid. This shift in the
mode of energy storage may result from a positive
feedback loop involving mTORC1 and its transcriptional
factor target SREBP1.
The activation of GS by insulin requires the localiza-
tion of PP1 to glycogen particles through glycogen-
targeting subunits, which act as molecular scaffolds to
unite PP1 with GS and GP for regulation (23). This study
confirms the crucial role of PTG in controlling glycogen
synthesis (4,5). PTG KO mice have markedly reduced
glycogen levels in liver. Moreover, biochemical evalua-
tion of GS localization in PTG KO mice demonstrates
conclusively that PTG is essential to direct GS to glyco-
gen particles in liver.
The present experiments also reveal the surprising
finding that the regulation of glycogen synthesis by
fasting/refeeding and HFD can be largely attributed to
changes in the expression of PTG. The increase in
glycogen levels found in the livers of HFD mice is
mirrored by increased expression of PTG but attenuated
in PTG KO mice. Both in vivo and in vitro studies re-
vealed an important role for mTORC1 in PTG expres-
sion, consistent with findings by us and others that
glycogen synthesis is sensitive to inhibition by rapamy-
cin (24–26). We propose that mTORC1 may regulate gly-
cogen metabolism through a transcriptional mTORC1/
SREBP/PTG pathway, which in turn modifies the phos-
phorylation status of GS in the glycogen compartment
(Fig. 8D). This idea is supported by studies in both em-
bryonic fibroblasts and mice in which there was a clear
causal relationship between mTORC1 function, SREBP,
and PTG levels and glycogen accumulation. The regula-
tion of SREBP processing by mTORC1 has been widely
studied in the context of lipid homeostasis (27,28). The
present data suggest that dietary modulations in
mTORC1 activity may affect not only lipid storage but
also carbohydrate storage through regulation of glycogen
synthesis.
Also surprising was the effect of PTG ablation on
glucose metabolism. PTG mice on the original mixed
background were homozygous lethal, so we studied the
heterozygous KOs and found that they have decreased
hepatic glycogen levels and a worsened metabolic
phenotype after $10 months of ND (11). However,
we were surprised to find after several years that the
homozygous PTG KO mice were viable by backcrossing
heterozygotes against C57BL6/J mice. After short-term
HFD, the new homozygous PTG KO mice showed
reduced hepatic glucose output compared with WT litter-
mates, but little effect on systemic insulin sensitivity,
likely reflecting reduced glycogen that serves as a source
of glucose. However, after longer-term HFD, PTG KO
mice exhibited profoundly reduced fasting glucose and
insulin levels along with improved glucose, pyruvate, and
insulin tolerance, reflecting increased systemic insulin
sensitivity. These were accompanied by changes in ex-
pression of genes involved in lipogenesis, glycolysis, in-
flammation, and macrophage infiltration. Thus, although
GS is increased while GP is decreased by insulin action,
and both enzymes have been considered as targets for
the treatment of type 2 diabetes, reducing glycogen syn-
thesis may paradoxically improve insulin resistance in
obesity.
The effect of PTG deletion on hepatic steatosis was
particularly intriguing. Because PTG does not interact
with lipid-metabolizing enzymes, it is likely that this
observation reflects crosstalk between pools of glycogen
and upstream nutrient-sensing pathways. These ideas
are consistent with observations from a study in which
administration of a GP inhibitor resulted in a short-
term reduction in blood glucose by preventing hepatic
glycogen breakdown, but this effect was accompanied
by steatosis after longer-term treatment due to in-
creased lipid synthesis (29). Glycogen levels are in-
creased in the livers of HFD mice under fasting
conditions, whereas the mTORC1 pathway is constitu-
tively elevated along with increased levels of PTG, sug-
gesting that diet-induced activation of mTORC1 may
increase glycogen stores in the fasted state by increas-
ing the levels of PTG. This occurs even in the face of
reduced insulin signaling in HFD and is similar to what
is observed for obesity-induced hepatic triglyceride ac-
cumulation [reviewed in Brown and Goldstein [30]).
Conversely, PTG KO mice, which have reduced levels
of hepatic glycogen, have reduced hepatic lipids and
reduced mTORC1/SREBP. Our transcriptional land-
scape analysis by RNA-seq revealed a significant down-
regulation of SREBP1 and numerous target genes
involved in lipogenesis. Although we cannot rule out
other mechanisms explaining reduced hepatic lipid lev-
els, such as reduced glucose and insulin levels, these
transcriptional changes most likely underlie the alter-
ations in lipid levels in PTG KO livers, which perhaps
reflect an interesting feedback regulation of PTG on
mTORC1/SREBP and lipogenesis to mediate crosstalk
between pools of glycogen and lipids.
How might mTORC1 sense levels of glycogen? We
propose a molecular sensor upstream of the mTORC1
complex, similar to what might be involved in the
sensing of amino acids (31). One possible candidate is
AMPK, a negative regulator of mTORC1 that is believed
to be directly attenuated by the binding of glycogen to
its b-subunit (32–34). Although we did not observe
a decrease in AMPK or acetyl-CoA carboxylase phos-
phorylation in liver from PTG mice fed a short-term
2946 PTG-Dependent Glycogen and Lipid Accumulation Diabetes Volume 63, September 2014
HFD, there were reductions in muscle tissue (data not
shown), suggesting that this enzyme may contribute to
the overall regulation of mTORC1. However, the possi-
bility remains that there are other glycogen sensors
in the mTOR pathway. Future studies will focus on
the regulation of this pathway by glycogen with the
hope of developing new therapeutic targets for the
treatment of insulin resistance and nonalcoholic fatty
liver disease.
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